Michael Morici
Overview
Explore the profile of Michael Morici including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langworthy K, Taggart M, Smith R, Levy A, Knight D, Hui S, et al.
J Infect Dis
. 2024 Oct;
PMID: 39383256
Background: Rising incidence of invasive beta-haemolytic streptococcal (iBHS) infections has prompted consideration of vaccination as a preventative strategy for at-risk populations. The benefits of a vaccine targeting Lancefield group A...
2.
Taggart M, Langworthy K, Hui S, Boyder C, Fulurija A, Morici M, et al.
Open Forum Infect Dis
. 2024 Jun;
11(6):ofae272.
PMID: 38872850
Background: A future (Strep A) vaccine will ideally prevent a significant burden of lower limb cellulitis; however, natural immune responses to proposed vaccine antigens following an episode of cellulitis remain...
3.
Acheampong E, Morici M, Abed A, Bowyer S, Asante D, Lin W, et al.
J Cancer Res Clin Oncol
. 2022 Jul;
149(5):1941-1950.
PMID: 35896898
Background: Circulating tumour cells (CTCs) are attractive "liquid biopsy" candidates that could provide insights into the different phenotypes of tumours present within a patient. The epithelial-to-mesenchymal transition (EMT) of CTCs...
4.
Acheampong E, Abed A, Morici M, Spencer I, Beasley A, Bowyer S, et al.
Transl Lung Cancer Res
. 2022 Apr;
11(3):440-451.
PMID: 35399573
Background: Antibodies against the programmed death-1 (PD-1) receptor and its ligand (PD-L1) have been recently approved for small-cell lung cancer (SCLC) treatment. Circulating tumour cells (CTCs) have emerged as an...
5.
Asante D, Morici M, Mohan G, Acheampong E, Spencer I, Lin W, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944844
Detection of ovarian cancer (OC) circulating tumour cells (CTCs) is primarily based on targeting epithelial markers, thus failing to detect mesenchymal tumour cells. More importantly, the immune checkpoint inhibitor marker...
6.
Morici M, Lin W, Gray E
Methods Mol Biol
. 2021 Mar;
2265:235-245.
PMID: 33704719
Circulating tumor cells (CTCs) are cancer cells shed by the primary tumor or its metastases that circulate in the peripheral blood. CTCs are potential seeds for metastases, and their detection...
7.
Mavropalias G, Calapre L, Morici M, Koeda T, Poon W, Barley O, et al.
Eur J Appl Physiol
. 2021 Jan;
121(4):1087-1097.
PMID: 33439308
Purpose: We examined changes in plasma creatine kinase (CK) activity, hydroxyproline and cell-free DNA (cfDNA) concentrations in relation to changes in maximum voluntary isometric contraction (MVIC) torque and delayed-onset muscle...
8.
Acheampong E, Abed A, Morici M, Bowyer S, Amanuel B, Lin W, et al.
Cells
. 2020 Nov;
9(11).
PMID: 33142852
Antibodies against programmed death-1 (PD-1), and its ligand, (PD-L1) have been approved recently for the treatment of small-cell lung cancer (SCLC). Although there are previous reports that addressed PD-L1 detection...
9.
Aya-Bonilla C, Morici M, Hong X, McEvoy A, Sullivan R, Freeman J, et al.
Br J Cancer
. 2020 Feb;
122(7):1059-1067.
PMID: 32037400
Background: Circulating tumour cells (CTCs) can be assessed through a minimally invasive blood sample with potential utility as a predictive, prognostic and pharmacodynamic biomarker. The large heterogeneity of melanoma CTCs...
10.
Fernando W, Martins I, Morici M, Bharadwaj P, Rainey-Smith S, Lim W, et al.
J Alzheimers Dis
. 2020 Jan;
74(1):91-99.
PMID: 31958090
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive decline and neuropathological features, including abnormal deposition of amyloid-β (Aβ) peptides, intracellular neurofibrillary tangles, and neuronal death. Identifying therapeutics...